MétaCan
Menu
Back to cohort
Record W3087074564 · doi:10.1093/brain/awaa231

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

2020· article· en· W3087074564 on OpenAlexaff
Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horáková, Eva Havrdová, María Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Özakbaş, Roberto Bergamaschi, María José Sá, Elisabetta Cartechini, Cavit Boz, Franco Granella, Raymond Hupperts, Murat Terzi, Jeannette Lechner‐Scott, Daniele Spitaleri, Vincent Van Pesch, Aysun Soysal, Javier Olascoaga, Julie Prévost, Eduardo Agüera, Mark Slee, Tünde Csépány, Recai Türkoğlu, Youssef Sidhom, Riadh Gouider, Bart Van Wijmeersch, Pamela McCombe, Richard Macdonell, Alasdair Coles, Charles B. Malpas, Helmut Butzkueven, Sandra Vukusic, Tomáš Kalinčík, Pierre Duquette, François Grand’Maison, Gerardo Iuliano, Cristina Ramo‐Tello, Claudio Solaro, José Antonio Cabrera-Gómez, Maria Edite Rio, R. Fernandez Bolanos, Vahid Shaygannejad, Celia Oreja‐Guevara, José Luis Sánchez-Menoyo, Thor Petersen, Ayşe Altıntaş, Michael Barnett, Shlomo Flechter, Yára Dadalti Fragoso, Maria Pia Amato, Fraser Moore, Radek Ampapa, Freek Verheul, Suzanne Hodgkinson, Edgardo Cristiano, Bassem Yamout, Guy Laureys, José Andrés Domínguez, Cees Zwanikken, Norma Deri, Enikő Dobos, Cárlos Vrech, Ernest Butler, Csilla Rózsa, Tatjana Petkovska‐Boskova, Rana Karabudak, Cecília Rajda, Jabir Alkhaboori, Maria Luisa Saladino, Cameron Shaw, Neil Shuey, Steve Vucic, Ángel Pérez Sempere, Jamie Campbell, Piroska Imre, Bruce Taylor, Anneke van der Walt, Ludwig Kappos, E Roullet, Orla Gray, Magdolna Simó, Carmen Adella Sîrbu, Bruno Brochet, François Cotton, de Sèze, Armelle Dion, Pascal Douek, Francis Guillemin, David Laplaud, Christine Lebrun‐Frénay, Thibault Moreau, Javier Olaiz, Jean Pelletier, Claire Rigaud-Bully, Bruno Stankoff, Romain Marignier, Marc Debouverie, Gilles Edan, Jonathan Ciron, Aurélie Ruet, Nicolas Collongues, Catherine Lubetzki, Patrick Vermersch, Pierre Labauge, Gilles Defer, Mikaël Cohen, Agnès Fromont, Sandrine Wiertlewsky, Eric Berger, Pierre Clavelou, Bertrand Audoin, C. Giannesini, Olivier Gout, Éric Thouvenot, Olivier Heinzlef, Abdullatif Al-Khedr, Bertrand Bourre, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Alain Créange, Jean-Philippe Camdessanché, Justine Faure, Aude Maurousset, I. Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle

Bibliographic record

VenueBrain · 2020
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsCegep de Saint JeromeCentre intégré de santé et de services sociaux de Chaudière-AppalachesUniversité de Montréal
FundersSanofi GenzymeNational Health and Medical Research CouncilMultiple Sclerosis International FederationAgence Nationale de la RechercheFondation pour l'Aide à la Recherche sur la Sclérose en PlaquesBiogenMerckSanofiTeva Pharmaceutical IndustriesNovartisRoche
KeywordsMultiple sclerosisMedicinePsychologyPhysical medicine and rehabilitationImmunology

Abstract

fetched live from OpenAlex

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 12 and 30 weeks. The duration of therapeutic lag for disability progression was calculated for seven therapies and ranged between 30 and 70 weeks. Significant differences in the pre- versus post-treatment annualized relapse rate were present for all therapies apart from intramuscular interferon beta-1a. In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progression in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience early on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.180
Threshold uncertainty score0.542

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.097
GPT teacher head0.324
Teacher spread0.227 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations40
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueBrainSame topicMultiple Sclerosis Research StudiesFrench-language works237,207